• +1-646-491-9876
    • +91-20-67278686

    Search

    Obesity Pipeline Review H1 2017

    Obesity Pipeline Review H1 2017

    • Report Code ID: RW0001799302
    • Category Pharmaceuticals
    • No. of Pages 494
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Obesity - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Obesity - Pipeline Review, H1 2017, provides an overview of the Obesity (Metabolic Disorders) pipeline landscape.

    Obesity is defined as having an excessive amount of body fat. Obesity increases risk of diseases and health problems such as heart disease, diabetes and high blood pressure. The predisposing factors include age, family history, quitting smoking, lack of sleep and certain medications. Treatment includes healthy lifestyle, medications and surgery.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Obesity - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 3, 16, 22, 129, 30 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 50 and 14 molecules, respectively.

    Obesity (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Obesity (Metabolic Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Obesity (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Obesity (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Obesity (Metabolic Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Obesity (Metabolic Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Obesity (Metabolic Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Obesity (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    Introduction 6
    Obesity - Overview 7
    Obesity - Therapeutics Development 8
    Obesity - Therapeutics Assessment 36
    Obesity - Companies Involved in Therapeutics Development 54
    Obesity - Drug Profiles 104
    Obesity - Dormant Projects 439
    Obesity - Discontinued Products 453
    Obesity - Product Development Milestones 457
    Appendix 467

    List of Tables

    Number of Products under Development for Obesity, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..5) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..6) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..5) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..6) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..7) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..8) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..9) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..10) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017 (Contd..2) , H1 2017
    Products under Development by Universities/Institutes, H1 2017 (Contd..3) , H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..3) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..4) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..5) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Obesity - Pipeline by Abeome Corp, H1 2017
    Obesity - Pipeline by Adamas Pharmaceuticals Inc, H1 2017
    Obesity - Pipeline by Advinus Therapeutics Ltd, H1 2017
    Obesity - Pipeline by Aegis Therapeutics LLC, H1 2017
    Obesity - Pipeline by Akron Molecules AG, H1 2017
    Obesity - Pipeline by Alize Pharma SAS, H1 2017
    Obesity - Pipeline by Amabiotics SAS, H1 2017
    Obesity - Pipeline by Amgen Inc, H1 2017
    Obesity - Pipeline by Aoxing Pharmaceutical Company Inc, H1 2017
    Obesity - Pipeline by Arrowhead Pharmaceuticals Inc, H1 2017
    Obesity - Pipeline by AstraZeneca Plc, H1 2017
    Obesity - Pipeline by Asubio Pharma Co Ltd, H1 2017
    Obesity - Pipeline by Athersys Inc, H1 2017
    Obesity - Pipeline by Biophytis SAS, H1 2017
    Obesity - Pipeline by BioRestorative Therapies Inc, H1 2017
    Obesity - Pipeline by Biozeus, H1 2017
    Obesity - Pipeline by Boehringer Ingelheim GmbH, H1 2017
    Obesity - Pipeline by Braasch Biotech LLC, H1 2017
    Obesity - Pipeline by C3J Therapeutics Inc, H1 2017
    Obesity - Pipeline by Camurus AB, H1 2017
    Obesity - Pipeline by Carmot Therapeutics Inc, H1 2017
    Obesity - Pipeline by CohBar Inc, H1 2017
    Obesity - Pipeline by CoMentis Inc, H1 2017
    Obesity - Pipeline by Connexios Life Sciences Pvt Ltd, H1 2017
    Obesity - Pipeline by ConSynance Therapeutics Inc, H1 2017
    Obesity - Pipeline by Corium International Inc, H1 2017
    Obesity - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
    Obesity - Pipeline by DiscoveryBiomed Inc, H1 2017
    Obesity - Pipeline by Eisai Co Ltd, H1 2017
    Obesity - Pipeline by Eli Lilly and Company, H1 2017
    Obesity - Pipeline by Esperion Therapeutics Inc, H1 2017
    Obesity - Pipeline by Eternygen GmbH, H1 2017
    Obesity - Pipeline by Evotec AG, H1 2017
    Obesity - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Obesity - Pipeline by FibroGen Inc, H1 2017
    Obesity - Pipeline by Genmedica Therapeutics SL, H1 2017
    Obesity - Pipeline by Gila Therapeutics Inc, H1 2017
    Obesity - Pipeline by Gilead Sciences Inc, H1 2017
    Obesity - Pipeline by GlaxoSmithKline Plc, H1 2017
    Obesity - Pipeline by Glucox Biotech AB, H1 2017
    Obesity - Pipeline by GTx Inc, H1 2017
    Obesity - Pipeline by HanAll Biopharma Co Ltd, H1 2017
    Obesity - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
    Obesity - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017
    Obesity - Pipeline by Immungenetics AG, H1 2017
    Obesity - Pipeline by Intarcia Therapeutics Inc, H1 2017
    Obesity - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
    Obesity - Pipeline by Ixchel Pharma LLC, H1 2017
    Obesity - Pipeline by Jenrin Discovery Inc, H1 2017
    Obesity - Pipeline by Johnson & Johnson, H1 2017
    Obesity - Pipeline by Laboratorios Silanes SA de CV, H1 2017
    Obesity - Pipeline by Lead Discovery Center GmbH, H1 2017
    Obesity - Pipeline by Leading BioSciences Inc, H1 2017
    Obesity - Pipeline by Lotus Pharmaceutical Co Ltd, H1 2017
    Obesity - Pipeline by M Pharmaceutical Inc, H1 2017
    Obesity - Pipeline by Magnus Life Ltd, H1 2017
    Obesity - Pipeline by MedImmune LLC, H1 2017
    Obesity - Pipeline by Merck & Co Inc, H1 2017
    Obesity - Pipeline by Mitochon Pharmaceuticals Inc, H1 2017
    Obesity - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
    Obesity - Pipeline by NeuroNano Pharma Inc, H1 2017
    Obesity - Pipeline by NGM Biopharmaceuticals Inc, H1 2017
    Obesity - Pipeline by NIBEC, H1 2017
    Obesity - Pipeline by Nordic Bioscience A/S, H1 2017
    Obesity - Pipeline by Novartis AG, H1 2017
    Obesity - Pipeline by Novo Nordisk A/S, H1 2017
    Obesity - Pipeline by ObeTherapy Biotechnology, H1 2017
    Obesity - Pipeline by Omeros Corp, H1 2017
    Obesity - Pipeline by OPKO Biologics Ltd, H1 2017
    Obesity - Pipeline by OPKO Health Inc, H1 2017
    Obesity - Pipeline by Pfizer Inc, H1 2017
    Obesity - Pipeline by PharmaIN Corp, H1 2017
    Obesity - Pipeline by Poxel SA, H1 2017
    Obesity - Pipeline by Progenra Inc, H1 2017
    Obesity - Pipeline by Prometheon Pharma LLC, H1 2017
    Obesity - Pipeline by ReCyte Therapeutics Inc, H1 2017
    Obesity - Pipeline by Renova Therapeutics Inc, H1 2017
    Obesity - Pipeline by Reviva Pharmaceuticals Inc, H1 2017
    Obesity - Pipeline by Saniona AB, H1 2017
    Obesity - Pipeline by Sanofi, H1 2017
    Obesity - Pipeline by Seoul Pharma Co Ltd, H1 2017
    Obesity - Pipeline by Shionogi & Co Ltd, H1 2017
    Obesity - Pipeline by Sinil Pharmaceutical Co Ltd, H1 2017
    Obesity - Pipeline by Sorrento Therapeutics Inc, H1 2017
    Obesity - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
    Obesity - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
    Obesity - Pipeline by Toray Industries Inc, H1 2017
    Obesity - Pipeline by Umecrine AB, H1 2017
    Obesity - Pipeline by Vicore Pharma AB, H1 2017
    Obesity - Pipeline by Viking Therapeutics Inc, H1 2017
    Obesity - Pipeline by WhanIn Pharmaceutical Co Ltd, H1 2017
    Obesity - Pipeline by Xenetic Biosciences Inc, H1 2017
    Obesity - Pipeline by XL-protein GmbH, H1 2017
    Obesity - Pipeline by Yuyu Pharma Inc, H1 2017
    Obesity - Pipeline by Zafgen Inc, H1 2017
    Obesity - Pipeline by Zealand Pharma AS, H1 2017
    Obesity - Dormant Projects, H1 2017
    Obesity - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Obesity - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Obesity - Dormant Projects, H1 2017 (Contd..3) , H1 2017
    Obesity - Dormant Projects, H1 2017 (Contd..4) , H1 2017
    Obesity - Dormant Projects, H1 2017 (Contd..5) , H1 2017
    Obesity - Dormant Projects, H1 2017 (Contd..6) , H1 2017
    Obesity - Dormant Projects, H1 2017 (Contd..7) , H1 2017
    Obesity - Dormant Projects, H1 2017 (Contd..8) , H1 2017
    Obesity - Dormant Projects, H1 2017 (Contd..9) , H1 2017
    Obesity - Dormant Projects, H1 2017 (Contd..10) , H1 2017
    Obesity - Dormant Projects, H1 2017 (Contd..11) , H1 2017
    Obesity - Dormant Projects, H1 2017 (Contd..12) , H1 2017
    Obesity - Dormant Projects, H1 2017 (Contd..13) , H1 2017
    Obesity - Discontinued Products, H1 2017
    Obesity - Discontinued Products, H1 2017 (Contd..1) , H1 2017
    Obesity - Discontinued Products, H1 2017 (Contd..2) , H1 2017
    Obesity - Discontinued Products, H1 2017 (Contd..3) , H1 2017

    List of Figures

    Number of Products under Development for Obesity, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    Abeome Corp
    Adamas Pharmaceuticals Inc
    Advinus Therapeutics Ltd
    Aegis Therapeutics LLC
    Akron Molecules AG
    Alize Pharma SAS
    Amabiotics SAS
    Amgen Inc
    Aoxing Pharmaceutical Company Inc
    Arrowhead Pharmaceuticals Inc
    AstraZeneca Plc
    Asubio Pharma Co Ltd
    Athersys Inc
    Biophytis SAS
    BioRestorative Therapies Inc
    Biozeus
    Boehringer Ingelheim GmbH
    Braasch Biotech LLC
    C3J Therapeutics Inc
    Camurus AB
    Carmot Therapeutics Inc
    CohBar Inc
    CoMentis Inc
    Connexios Life Sciences Pvt Ltd
    ConSynance Therapeutics Inc
    Corium International Inc
    Daiichi Sankyo Company Ltd
    DiscoveryBiomed Inc
    Eisai Co Ltd
    Eli Lilly and Company
    Esperion Therapeutics Inc
    Eternygen GmbH
    Evotec AG
    F. Hoffmann-La Roche Ltd
    FibroGen Inc
    Genmedica Therapeutics SL
    Gila Therapeutics Inc
    Gilead Sciences Inc
    GlaxoSmithKline Plc
    Glucox Biotech AB
    GTx Inc
    HanAll Biopharma Co Ltd
    Hanmi Pharmaceuticals Co Ltd
    Hyundai Pharmaceutical Co Ltd
    Immungenetics AG
    Intarcia Therapeutics Inc
    Ionis Pharmaceuticals Inc
    Ixchel Pharma LLC
    Jenrin Discovery Inc
    Johnson & Johnson
    Laboratorios Silanes SA de CV
    Lead Discovery Center GmbH
    Leading BioSciences Inc
    Lotus Pharmaceutical Co Ltd
    M Pharmaceutical Inc
    Magnus Life Ltd
    MedImmune LLC
    Merck & Co Inc
    Mitochon Pharmaceuticals Inc
    Mitsubishi Tanabe Pharma Corp
    NeuroNano Pharma Inc
    NGM Biopharmaceuticals Inc
    NIBEC
    Nordic Bioscience A/S
    Novartis AG
    Novo Nordisk A/S
    ObeTherapy Biotechnology
    Omeros Corp
    OPKO Biologics Ltd
    OPKO Health Inc
    Pfizer Inc
    PharmaIN Corp
    Poxel SA
    Progenra Inc
    Prometheon Pharma LLC
    ReCyte Therapeutics Inc
    Renova Therapeutics Inc
    Reviva Pharmaceuticals Inc
    Saniona AB
    Sanofi
    Seoul Pharma Co Ltd
    Shionogi & Co Ltd
    Sinil Pharmaceutical Co Ltd
    Sorrento Therapeutics Inc
    Sumitomo Dainippon Pharma Co Ltd
    Takeda Pharmaceutical Company Ltd
    Toray Industries Inc
    Umecrine AB
    Vicore Pharma AB
    Viking Therapeutics Inc
    WhanIn Pharmaceutical Co Ltd
    Xenetic Biosciences Inc
    XL-protein GmbH
    Yuyu Pharma Inc
    Zafgen Inc
    Zealand Pharma AS

    Request for Sample

    Report Url http://www.reportsweb.com//obesity-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//obesity-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//obesity-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments